General Information of Drug Transporter (DT)
DT ID	DTD0534 Transporter Info
Gene Name	CACNA1C
Protein Name	Voltage-gated calcium channel alpha Cav1.2
Gene ID	775
UniProt ID	Q13936
Genetic Polymorphisms of DT (GPD)
Genetic Polymorphism	rs2238087
Site of GPD	chr12:2504550 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>G / C>T
Minor Allele Frequency	T=0.0531/238 (Global)
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Antipsychotics	N.A.	Torsades De Pointes	Genotype CC is associated with increased response to antipsychotics in people with Schizophrenia as compared to genotype TT.		[ 1]
Antipsychotics	N.A.	Schizophrenia	Correlated with the increased drug response in patients (compare with genotype TT)		[ 1]
Genetic Polymorphism	rs215976
Site of GPD	chr12:2585472 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	C=0.8610/1703 (Global)
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Ritodrine	N.A.	Adverse Events	Genotype TT is not associated with likelihood of adverse events when treated with ritodrine in women with Premature Birth as compared to genotypes CC + CT.		[ 2]
Allele C	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Antiepileptics	N.A.	Adverse Events	Allele C is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele T.		[ 3]
Genetic Polymorphism	rs215994
Site of GPD	chr12:2607994 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>A / T>C
Minor Allele Frequency	T=0.7440/1472 (Global)
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Ritodrine	N.A.	Adverse Events	Genotype CC is not associated with likelihood of adverse events when treated with ritodrine in women with Premature Birth as compared to genotypes CT + TT.		[ 2]
Genetic Polymorphism	rs2041135
Site of GPD	chr12:1992332 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C
Minor Allele Frequency	T=0.8630/1707 (Global)
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Ritodrine	N.A.	Adverse Events	Genotype CC is not associated with likelihood of adverse events when treated with ritodrine in women with Premature Birth as compared to genotypes CT + TT.		[ 2]
Genetic Polymorphism	rs1051375
Site of GPD	chr12:2679713 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A / G>C
Minor Allele Frequency	G=0.4800/949 (Global)
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           6 Drugs in Total
Valproic Acid	N.A.	Adverse Events	Genotype AA is associated with increased resistance to valproic acid in people with Epilepsy as compared to genotypes AG + GG.		[ 4]
Verapamil	N.A.	Torsades De Pointes	Genotype AA is associated with decreased risk of primary outcome when treated with verapamil in people with Coronary Artery Disease.		[ 5]
Atenolol	N.A.	Coronary Artery Disease	Genotype AA is associated with decreased risk of primary outcome when treated with verapamil in people with Coronary Artery Disease.		[ 5]
Atenolol	N.A.	Hypertension	Genotype AA is associated with decreased risk of primary outcome when treated with verapamil in people with Coronary Artery Disease.		[ 5]
Verapamil	N.A.	Coronary Artery Disease	Genotype AA is associated with decreased risk of primary outcome when treated with verapamil in people with Coronary Artery Disease.		[ 5]
Verapamil	N.A.	Hypertension	Genotype AA is associated with decreased risk of primary outcome when treated with verapamil in people with Coronary Artery Disease.		[ 5]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           5 Drugs in Total
Verapamil	N.A.	Torsades De Pointes	Genotype AG is not associated with increased risk of primary outcome when treated with verapamil in people with Coronary Artery Disease.		[ 5]
Atenolol	N.A.	Coronary Artery Disease	Genotype AG is not associated with increased risk of primary outcome when treated with verapamil in people with Coronary Artery Disease.		[ 5]
Atenolol	N.A.	Hypertension	Genotype AG is not associated with increased risk of primary outcome when treated with verapamil in people with Coronary Artery Disease.		[ 5]
Verapamil	N.A.	Coronary Artery Disease	Genotype AG is not associated with increased risk of primary outcome when treated with verapamil in people with Coronary Artery Disease.		[ 5]
Verapamil	N.A.	Hypertension	Genotype AG is not associated with increased risk of primary outcome when treated with verapamil in people with Coronary Artery Disease.		[ 5]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           5 Drugs in Total
Verapamil	N.A.	Torsades De Pointes	Genotype GG is associated with increased risk of primary outcome when treated with verapamil in people with Coronary Artery Disease.		[ 5]
Atenolol	N.A.	Coronary Artery Disease	Genotype GG is associated with increased risk of primary outcome when treated with verapamil in people with Coronary Artery Disease.		[ 5]
Atenolol	N.A.	Hypertension	Genotype GG is associated with increased risk of primary outcome when treated with verapamil in people with Coronary Artery Disease.		[ 5]
Verapamil	N.A.	Coronary Artery Disease	Genotype GG is associated with increased risk of primary outcome when treated with verapamil in people with Coronary Artery Disease.		[ 5]
Verapamil	N.A.	Hypertension	Genotype GG is associated with increased risk of primary outcome when treated with verapamil in people with Coronary Artery Disease.		[ 5]
Genetic Polymorphism	rs10774053
Site of GPD	chr12:2681966 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G
Minor Allele Frequency	A=0.2230/441 (Global)
Genotypes AA + AG	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Ritodrine	N.A.	Adverse Events	Genotypes AA + AG are associated with decreased likelihood of adverse events when treated with ritodrine in women with Premature Birth as compared to genotype GG.		[ 2]
Ritodrine	N.A.	Premature Birth	Genotypes AA + AG are associated with decreased likelihood of adverse events when treated with ritodrine in women with Premature Birth as compared to genotype GG.		[ 2]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Ritodrine	N.A.	Adverse Events	Women with premature births and the AA genotype who are treated with ritodrine may have a decreased likelihood of adverse events as compared to women with premature birth and the GG genotype. Other clinical and genetic factors may also influence the likelihood of adverse events in women with premature labor who are treated with ritodrine.		[ 2]
Ritodrine	N.A.	Premature Birth	Women with premature births and the AA genotype who are treated with ritodrine may have a decreased likelihood of adverse events as compared to women with premature birth and the GG genotype. Other clinical and genetic factors may also influence the likelihood of adverse events in women with premature labor who are treated with ritodrine.		[ 2]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Ritodrine	N.A.	Adverse Events	Women with premature births and the AG genotype who are treated with ritodrine may have a decreased likelihood of adverse events as compared to women with premature birth and the GG genotype. Other clinical and genetic factors may also influence the likelihood of adverse events in women with premature labor who are treated with ritodrine.		[ 2]
Ritodrine	N.A.	Premature Birth	Women with premature births and the AG genotype who are treated with ritodrine may have a decreased likelihood of adverse events as compared to women with premature birth and the GG genotype. Other clinical and genetic factors may also influence the likelihood of adverse events in women with premature labor who are treated with ritodrine.		[ 2]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Ritodrine	N.A.	Adverse Events	Women with premature births and the GG genotype who are treated with ritodrine may have a increased likelihood of adverse events as compared to women with premature birth and the AA or AG genotype. Other clinical and genetic factors may also influence the likelihood of adverse events in women with premature labor who are treated with ritodrine.		[ 2]
Ritodrine	N.A.	Premature Birth	Women with premature births and the GG genotype who are treated with ritodrine may have a increased likelihood of adverse events as compared to women with premature birth and the AA or AG genotype. Other clinical and genetic factors may also influence the likelihood of adverse events in women with premature labor who are treated with ritodrine.		[ 2]
Genetic Polymorphism	rs2239128
Site of GPD	chr12:2648603 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>A / T>C
Minor Allele Frequency	T=0.3340/660 (Global)
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Ritodrine	N.A.	Adverse Events	Genotype CC is not associated with likelihood of adverse events when treated with ritodrine in women with Premature Birth as compared to genotypes CT + TT.		[ 2]
Nimodipine	N.A.	Adverse Events	Genotype CC is associated with increased response to nimodipine in healthy individuals as compared to genotype CT.		[ 7]
Calcium Channel Blockers	N.A.	Hypertension	Patients with the CC genotype and hypertension may have a better blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, lacidipine, nifedipine or nitrendipine, as compared to patients with the TT genotype. However, no significant association was seen in a subpopulation of patients taking only lacidipine, nifedipine or nitrendipine. Other genetic and clinical factors may also influence blood pressure response.		[ 8]
Allele C	Click to Show/Hide the Full List of Affected Drugs:           8 Drugs in Total
Amlodipine	N.A.	Adverse Events	Allele C is associated with increased response to amlodipine and felodipine in people with Hypertension as compared to allele T.		[ 7]
Felodipine	N.A.	Adverse Events	Allele C is associated with increased response to amlodipine and felodipine in people with Hypertension as compared to allele T.		[ 7]
Lacidipine	N.A.	Adverse Events	Allele C is not associated with response to lacidipine, nifedipine or nitrendipine in people with Hypertension as compared to allele T.		[ 7]
Nifedipine	N.A.	Adverse Events	Allele C is not associated with response to lacidipine, nifedipine or nitrendipine in people with Hypertension as compared to allele T.		[ 7]
Nitrendipine	N.A.	Adverse Events	Allele C is not associated with response to lacidipine, nifedipine or nitrendipine in people with Hypertension as compared to allele T.		[ 7]
Antiepileptics	N.A.	Adverse Events	Allele C is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele T.		[ 3]
Calcium Channel Blockers	N.A.	Torsades De Pointes	Allele C is associated with increased response to calcium channel blockers in people with Hypertension as compared to allele T.		[ 7]
Calcium Channel Blockers	N.A.	Hypertension	Allele C is associated with increased response to amlodipine and felodipine in people with Hypertension as compared to allele T.		[ 7]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Nimodipine	N.A.	Major Depressive Disorder	Patients with the CT genotype may have increased systolic blood pressure following nimodipine administration as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's blood pressure following nimodipine administration.		[ 6]
Calcium Channel Blockers	N.A.	Hypertension	Patients with the CT genotype and hypertension may have a better blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, lacidipine, nifedipine or nitrendipine, as compared to patients with the TT genotype, or a poorer blood pressure response compared to patients with the CC genotype. Other genetic and clinical factors may also influence blood pressure response.		[ 7]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Nimodipine	N.A.	Major Depressive Disorder	There is currently no available evidence regarding the association between the TT genotype and response to nimodipine.		[ 6]
Calcium Channel Blockers	N.A.	Hypertension	Patients with the TT genotype and hypertension may have a poorer blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, lacidipine, nifedipine or nitrendipine, as compared to patients with the CC genotype. However, no significant association was seen in a subpopulation of patients taking only lacidipine, nifedipine or nitrendipine. Other genetic and clinical factors may also influence blood pressure response.		[ 7]
Genetic Polymorphism	rs2239050
Site of GPD	chr12:2338248 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A / G>C
Minor Allele Frequency	G=0.6850/1355 (Global)
Genotype CG	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Nimodipine	N.A.	Adverse Events	Genotype CG is associated with increased response to nimodipine in healthy individuals as compared to genotype CC.		[ 6]
Calcium Channel Blockers	N.A.	Hypertension	Genotype CG is associated with increased response to nimodipine in healthy individuals as compared to genotype CC.		[ 6]
Calcium Channel Blockers	N.A.	Hypertension	Patients with the rs2239050 CG genotype and hypertension may have a poorer blood pressure response when treated with calcium channel blockers as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence blood pressure response.		[ 9]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           7 Drugs in Total
Amlodipine	N.A.	Adverse Events	Genotype GG is associated with increased response to amlodipine and felodipine in people with Hypertension as compared to genotype CG.		[ 7]
Felodipine	N.A.	Adverse Events	Genotype GG is associated with increased response to amlodipine and felodipine in people with Hypertension as compared to genotype CG.		[ 7]
Calcium Channel Blockers	N.A.	Torsades De Pointes	Genotype GG is associated with increased response to calcium channel blockers in people with Hypertension as compared to genotypes CC + CG.		[ 7]
Amlodipine	N.A.	Torsades De Pointes	Genotype GG is associated with increased clinical benefit to amlodipine in people with Hypertension as compared to genotypes CC + CG.		[ 8]
Nimodipine	N.A.	Hypertension	There is currently no available evidence regarding the association of the rs2239050 GG genotype and response to nimodipine.		[ 6]
Calcium Channel Blockers	N.A.	Hypertension	Genotype GG is associated with increased clinical benefit to amlodipine in people with Hypertension as compared to genotypes CC + CG.		[ 8]
Calcium Channel Blockers	N.A.	Hypertension	Genotype GG is associated with increased response to amlodipine and felodipine in people with Hypertension as compared to genotype CG.		[ 7]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           6 Drugs in Total
Lacidipine	N.A.	Adverse Events	Genotype CC is not associated with response to lacidipine, nifedipine or nitrendipine in people with Hypertension as compared to genotype CG.		[ 7]
Nifedipine	N.A.	Adverse Events	Genotype CC is not associated with response to lacidipine, nifedipine or nitrendipine in people with Hypertension as compared to genotype CG.		[ 7]
Nitrendipine	N.A.	Adverse Events	Genotype CC is not associated with response to lacidipine, nifedipine or nitrendipine in people with Hypertension as compared to genotype CG.		[ 7]
Nimodipine	N.A.	Hypertension	Patients with the rs2239050 CC genotype may have a decreased response to nimodipine as compared to patients with the CG genotype. Other genetic and clinical factors may also affect response to nimodipine.		[ 6]
Calcium Channel Blockers	N.A.	Hypertension	Genotype CC is not associated with response to lacidipine, nifedipine or nitrendipine in people with Hypertension as compared to genotype CG.		[ 7]
Calcium Channel Blockers	N.A.	Hypertension	Patients with the rs2239050 CC genotype and hypertension may have a poorer blood pressure response when treated with calcium channel blockers as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence blood pressure response.		[ 8]
Genetic Polymorphism	rs2238032
Site of GPD	chr12:2113566 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C / T>G
Minor Allele Frequency	T=0.9290/1838 (Global)
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           9 Drugs in Total
Nimodipine	N.A.	Adverse Events	Genotype TT is not associated with response to nimodipine in healthy individuals as compared to genotype GT.		[ 6]
Lacidipine	N.A.	Adverse Events	Genotype TT is associated with increased response to lacidipine, nifedipine or nitrendipine in people with Hypertension as compared to genotypes GG + GT.		[ 7]
Nifedipine	N.A.	Adverse Events	Genotype TT is associated with increased response to lacidipine, nifedipine or nitrendipine in people with Hypertension as compared to genotypes GG + GT.		[ 7]
Nitrendipine	N.A.	Adverse Events	Genotype TT is associated with increased response to lacidipine, nifedipine or nitrendipine in people with Hypertension as compared to genotypes GG + GT.		[ 7]
Amlodipine	N.A.	Torsades De Pointes	Genotype TT is associated with increased response to amlodipine or felodipine in people with Hypertension as compared to genotypes GG + GT.		[ 7]
Felodipine	N.A.	Torsades De Pointes	Genotype TT is associated with increased response to amlodipine or felodipine in people with Hypertension as compared to genotypes GG + GT.		[ 7]
Calcium Channel Blockers	N.A.	Torsades De Pointes	Genotype TT is associated with increased response to calcium channel blockers in people with Hypertension as compared to genotypes GG + GT.		[ 7]
Calcium Channel Blockers	N.A.	Hypertension	Genotype TT is associated with increased response to amlodipine or felodipine in people with Hypertension as compared to genotypes GG + GT.		[ 7]
Calcium Channel Blockers	N.A.	Hypertension	Genotype TT is not associated with response to nimodipine in healthy individuals as compared to genotype GT.		[ 6]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Calcium Channel Blockers	N.A.	Hypertension	Patients with the GG genotype and hypertension may have a poorer blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, lacidipine, nifedipine or nitrendipine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to calcium channel blockers.		[ 7]
Genotype GT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Calcium Channel Blockers	N.A.	Hypertension	Patients with the GT genotype and hypertension may have a poorer blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, lacidipine, nifedipine or nitrendipine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to calcium channel blockers.		[ 7]
Genetic Polymorphism	rs216013
Site of GPD	chr12:2620466 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G
Minor Allele Frequency	A=0.7750/1533 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Warfarin	N.A.	Adverse Events	Allele A is not associated with dose of warfarin.		[ 9]
Genetic Polymorphism	rs216008
Site of GPD	chr12:2611971 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	C=0.7430/1470 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Antiepileptics	N.A.	Adverse Events	Allele C is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele T.		[ 3]
Genetic Polymorphism	rs7316246
Site of GPD	chr12:2695289 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A / G>C
Minor Allele Frequency	G=0.8900/1761 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Antiepileptics	N.A.	Adverse Events	Allele G is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele A.		[ 3]
Genetic Polymorphism	rs12813888
Site of GPD	chr12:2627452 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>C / A>T
Minor Allele Frequency	A=0.7970/1577 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Antiepileptics	N.A.	Adverse Events	Allele A is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele C.		[ 3]
Genetic Polymorphism	rs7295250
Site of GPD	chr12:2667777 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C / T>G
Minor Allele Frequency	T=0.4940/977 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           6 Drugs in Total
Amiodarone	N.A.	Torsades De Pointes	Allele T is associated with increased risk of Torsades de Pointes when treated with amiodarone, Antibiotics, antipsychotics, diuretics, quinidine or sotalol as compared to allele C.		[ 10]
Antibiotics	N.A.	Torsades De Pointes	Allele T is associated with increased risk of Torsades de Pointes when treated with amiodarone, Antibiotics, antipsychotics, diuretics, quinidine or sotalol as compared to allele C.		[ 10]
Antipsychotics	N.A.	Torsades De Pointes	Allele T is associated with increased risk of Torsades de Pointes when treated with amiodarone, Antibiotics, antipsychotics, diuretics, quinidine or sotalol as compared to allele C.		[ 10]
Diuretics	N.A.	Torsades De Pointes	Allele T is associated with increased risk of Torsades de Pointes when treated with amiodarone, Antibiotics, antipsychotics, diuretics, quinidine or sotalol as compared to allele C.		[ 10]
Quinidine	N.A.	Torsades De Pointes	Allele T is associated with increased risk of Torsades de Pointes when treated with amiodarone, Antibiotics, antipsychotics, diuretics, quinidine or sotalol as compared to allele C.		[ 10]
Sotalol	N.A.	Torsades De Pointes	Allele T is associated with increased risk of Torsades de Pointes when treated with amiodarone, Antibiotics, antipsychotics, diuretics, quinidine or sotalol as compared to allele C.		[ 10]
Genetic Polymorphism	rs1034936
Site of GPD	chr12:2551994 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>A / C>G / C>T
Minor Allele Frequency	C=0.4090/809 (Global)
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Ethanol	N.A.	Alcohol Abuse	Genotype TT is associated with increased risk of Alcoholism due to ethanol in people with Bipolar Disorder as compared to genotypes CC + CT.		[ 11]
Ethanol	N.A.	Bipolar Disorder	Genotype TT is associated with increased risk of Alcoholism due to ethanol in people with Bipolar Disorder as compared to genotypes CC + CT.		[ 11]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Ethanol	N.A.	Alcohol Abuse	Patients with bipolar disorder and the CC genotype may be at a decreased risk of developing alcohol dependence as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.		[ 11]
Ethanol	N.A.	Bipolar Disorder	Patients with bipolar disorder and the CC genotype may be at a decreased risk of developing alcohol dependence as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.		[ 11]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Ethanol	N.A.	Alcohol Abuse	Patients with bipolar disorder and the CT genotype may be at a decreased risk of developing alcohol dependence as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.		[ 11]
Ethanol	N.A.	Bipolar Disorder	Patients with bipolar disorder and the CT genotype may be at a decreased risk of developing alcohol dependence as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.		[ 11]
Genetic Polymorphism	rs723672
Site of GPD	chr12:2052395 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>A / C>G / C>T
Minor Allele Frequency	C=0.3720/736 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Olanzapine	N.A.	Alcohol Abuse	Allele C is not associated with response to olanzapine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.		[ 12]
Quetiapine	N.A.	Alcohol Abuse	Allele C is not associated with response to olanzapine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.		[ 12]
Risperidone	N.A.	Alcohol Abuse	Allele C is not associated with response to olanzapine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.		[ 12]
Genetic Polymorphism	rs2283271
Site of GPD	chr12:2073132 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>A
Minor Allele Frequency	T=0.2990/591 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Olanzapine	N.A.	Alcohol Abuse	Allele A is not associated with response to olanzapine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.		[ 12]
Quetiapine	N.A.	Alcohol Abuse	Allele A is not associated with response to olanzapine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.		[ 12]
Risperidone	N.A.	Alcohol Abuse	Allele A is not associated with response to olanzapine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.		[ 12]
Genetic Polymorphism	rs758723
Site of GPD	chr12:2111239 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>A / T>C
Minor Allele Frequency	T=0.4620/914 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Olanzapine	N.A.	Alcohol Abuse	Allele A is not associated with response to olanzapine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.		[ 12]
Quetiapine	N.A.	Alcohol Abuse	Allele A is not associated with response to olanzapine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.		[ 12]
Risperidone	N.A.	Alcohol Abuse	Allele A is not associated with response to olanzapine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.		[ 12]
Genetic Polymorphism	rs10848635
Site of GPD	chr12:2207029 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>A / T>C
Minor Allele Frequency	T=0.6710/1327 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           5 Drugs in Total
Olanzapine	N.A.	Alcohol Abuse	Allele A is not associated with response to olanzapine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.		[ 12]
Quetiapine	N.A.	Alcohol Abuse	Allele A is not associated with response to olanzapine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.		[ 12]
Risperidone	N.A.	Alcohol Abuse	Allele A is not associated with response to olanzapine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.		[ 12]
Citalopram	N.A.	Alcohol Abuse	Allele A is associated with increased risk of suicide when treated with citalopram in people with Depressive Disorder, Major as compared to allele T.		[ 14]
Citalopram	N.A.	Major Depressive Disorder	Allele A is associated with increased risk of suicide when treated with citalopram in people with Depressive Disorder, Major as compared to allele T.		[ 14]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Citalopram	N.A.	Major Depressive Disorder	Patients with the AA genotype and major depression may have increased risk of suicide when treated with citalopram as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.		[ 13]
Genotype AT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Citalopram	N.A.	Major Depressive Disorder	Patients with the AT genotype and major depression may have increased risk of suicide when treated with citalopram as compared to patients with the TT genotype or may have decreased, but not absent, risk of suicide when treated with citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.		[ 13]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Citalopram	N.A.	Major Depressive Disorder	Patients with the TT genotype and major depression may have decreased, but not absent, risk of suicide when treated with citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.		[ 13]
Genetic Polymorphism	rs1006737
Site of GPD	chr12:2236129 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	G=0.6890/1363 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Citalopram	N.A.	Alcohol Abuse	Allele A is associated with increased risk of suicide when treated with citalopram in people with Depressive Disorder, Major as compared to allele G.		[ 13]
Citalopram	N.A.	Major Depressive Disorder	Allele A is associated with increased risk of suicide when treated with citalopram in people with Depressive Disorder, Major as compared to allele G.		[ 13]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Citalopram	N.A.	Major Depressive Disorder	Patients with the AA genotype and major depression may have increased risk for suicide when treated with citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response citalopram.		[ 13]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Citalopram	N.A.	Major Depressive Disorder	Patients with the AG genotype and major depression may have increased risk for suicide when treated with citalopram as compared to patients with the GG genotype or may have decreased, but not absent, risk for suicide when treated with citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response citalopram.		[ 13]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Citalopram	N.A.	Major Depressive Disorder	Patients with the GG genotype and major depression may have decreased, but not absent, risk for suicide when treated with citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response citalopram.		[ 13]
References
1	Variation within voltage-gated calcium channel genes and antipsychotic treatment response in a South African first episode schizophrenia cohort. Pharmacogenomics J. 2019 Feb;19(1):109-114.
2	Association between CACNA1C gene polymorphisms and ritodrine-induced adverse events in preterm labor patients. Eur J Clin Pharmacol. 2017 Jul;73(7):837-842.
3	Association study between polymorphisms in the CACNA1A, CACNA1C, and CACNA1H genes and drug-resistant epilepsy in the Chinese Han population. Seizure. 2015 Aug;30:64-9.
4	Association of valproic acid-related pharmacodynamics, pharmacokinetic pathways and transporter gene polymorphisms and antiepileptic efficacy in Chinese patients. Xenobiotica. 2025 Jun 23:1-12.
5	CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response. Circ Cardiovasc Genet. 2009 Aug;2(4):362-70.
6	Effects of CYP3A5, MDR1 and CACNA1C polymorphisms on the oral disposition and response of nimodipine in a Chinese cohort. Eur J Clin Pharmacol. 2009 Jun;65(6):579-84.
7	CACNA1C polymorphisms are associated with the efficacy of calcium channel blockers in the treatment of hypertension. Pharmacogenomics. 2006 Apr;7(3):271-9.
8	Pharmacogenomic Study of Selected Genes Affecting Amlodipine Blood Pressure Response in Patients with Hypertension. Pharmgenomics Pers Med. 2024;17:473-486.
9	A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood. 2008 Aug 15;112(4):1022-7.
10	A large candidate gene survey identifies the KCNE1 D85N polymorphism as a possible modulator of drug-induced torsades de pointes. Circ Cardiovasc Genet. 2012 Feb 01;5(1):91-9.
11	Association between CANCA1C gene rs1034936 polymorphism and alcohol dependence in bipolar disorder. J Affect Disord. 2020 Jan 15;261:181-186.
12	CACNA1C gene and schizophrenia: a case-control and pharmacogenetic study. Psychiatr Genet. 2015 Aug;25(4):163-7.
13	Phenotypic effects of a bipolar liability gene among individuals with major depressive disorder. Am J Med Genet B Neuropsychiatr Genet. 2010 Jan 05;153B(1):303-9.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.